16 results about "Preeclampsia" patented technology

The invention discloses application of C1INH in preparation of a product for prediction or auxiliary diagnosis of preeclampsia and the product, belongs to the technical field of biological medicines, and aims to detect the content of C1INH in a blood sample on a protein level by taking the blood sample of a subject as a detection object. According to the invention, C1INH molecules in blood are taken as a detection index, prediction and auxiliary diagnosis of preeclampsia of pregnant women can be realized, high sensitivity and specificity are realized, rapid detection can be realized, and a new way is provided for early screening and diagnosis of preeclampsia in the prior art.

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.

The present invention relates to a disease-specific biomarker for early prediction and diagnosis of preeclampsia and use thereof, and a composition for prediction or diagnosis of preeclampsia according to an aspect or a method of providing information for prediction or diagnosis thereof, can simply and effectively predict or diagnose the disease by measuring and comparing the mRNA level of a disease-specific protein or a gene encoding the protein changed in a patient.

The application discloses a kind of based on HAPLN1 down-regulation induced preeclampsia animal model construction method and application of placental cell abnormal aging, belong to the field of biological medicine technology.The application can stably induce the animal model with typical preeclampsia clinical characteristics by reducing the expression level of HAPLN1 in pregnant mice, while reproducing the abnormal phenotype of placental cell aging.The method has strong controllability in operation process, and the model has good reproducibility, which can provide effective experimental tools for in-depth study of the pathogenesis of preeclampsia and development of new diagnosis and treatment strategies.

The application discloses a feature selection method and device for predicting preeclampsia risk of pregnant women, and relates to the technical field of data processing.The application uses an adaptive network topology strategy to construct a topology structure, and dynamically constructs sparse adjacency relations between individuals based on fitness and similarity to generate a topology population.The topology structure reflects the internal interaction correlation between features, can guide the algorithm to perform self-organizing directional search according to a search state, and realizes the unified balance of exploration and development.Then, a positive sine search mechanism is used to perform periodic jump search between global search and local search under the guidance of a global optimal solution, and a multi-level information interaction strategy is used, global items promote convergence to the optimal solution, local items strengthen mining of potential local areas, global information dissemination and local neighborhood learning are fused and unified, and dynamic balance search between global search and local search is realized, so that key features are finally identified.

Described herein are lateral flow devices, kits, systems and methods for measuring levels of sFlt-1 in a plasma or serum sample and prognosticating a women's risk of having sPE.

A system and method of generating a model M that can detect or predict the predisposition to an outcome, for example a person's predisposition to developing a health condition such as preeclampsia, with a positive or / and negative predictive value better or equal to a predefined predictive value target, where the method factors in the impact of prevalence on test performance. The system and method employ an iterative population segregation methodology, involving at least two population segregations steps in which each step, independently, employs a probability-defined model. The first segregation step is selected from one of a rule-in probability defined model and a rule-out probability defined model, and the second segregation step is selected from the other of a rule-in probability defined model and a rule-out probability defined model. The present invention overcomes the technical limitations of existing predictive models and provides a solution to achieve a superior predictive model delivering an accurate risk prediction result, and in a less computationally intensive way. By isolating and segmenting particular population subsets according to the invention a much more robust and accurate way of detecting, or predict risk of, an outcome is achieved.

This invention belongs to the pharmaceutical field, specifically relating to the application of phosphopamine hydrochloride in the preparation of drugs for treating preeclampsia. The application of phosphopamine hydrochloride in the preparation of drugs for treating preeclampsia involves the phosphopamine hydrochloride exerting its effect by promoting trophoblast motility. This effect is achieved by regulating the lactation modification of α-actin-4. The phosphopamine hydrochloride salvages trophoblast functional damage in preeclampsia by inhibiting lactation at the ACTN4 K346 site. This invention reveals for the first time that the lactation modification at the ACTN4 protein K346 site is abnormally elevated in placental tissue of PE patients. This modification can impair trophoblast function and drive disease progression. Phosphopamine hydrochloride can target and inhibit lactation modification at this site, reversing trophoblast functional damage and demonstrating good therapeutic potential.

This invention belongs to the field of biodetection technology and discloses a risk biomarker for pregnancy complications and its application. The invention provides a risk biomarker for pregnancy complications, namely, serum fluorescence lifetime; the pregnancy complications include preeclampsia, gestational diabetes mellitus, and preeclampsia combined with gestational diabetes mellitus. This invention uses fluorescence lifetime imaging technology to characterize functional changes in the lipid-related microenvironment in maternal serum, enabling the detection of metabolic disturbance signals in the early stages of pregnancy before routine clinical indicators show abnormalities, thereby advancing the disease identification time window. This invention effectively overcomes the problem of difficulty in achieving effective early warning in the subclinical stage of disease in existing technologies, providing a new technical approach for early warning and individualized management of pregnancy complications.

A method for diagnosing or predicting preeclampsia in a pregnant woman or determining whether a pregnant woman is at risk of developing preeclampsia is provided, comprising: a) obtaining at least one (such as two or more) maternal or fetal parameter or factor of the pregnant woman selected from the group comprising: (i) one or more of mean arterial pressure, BMI at sampling, ΔBMI, gestational age, and ΔBMI / GA; (ii) maternal age; (iii) one or more of urinary protein level and ratio of urinary protein level (such as total urinary protein) to urinary creatinine level; (iv) one or more of history of preeclampsia in previous pregnancies and having received antihypertensive medication; and (v) any combination of (i)-(iv), b) determining whether the pregnant woman has misfolded proteins or misfolded protein aggregates in her urine, and c) combining the at least one maternal or fetal parameter or factor obtained in step a) with the level of misfolded proteins or misfolded protein aggregates in the pregnant woman's urine to diagnose or predict preeclampsia or determine the risk of preeclampsia.

The application discloses a feature selection method, system, device and medium for clinical prediction of preeclampsia, relates to the technical field of feature selection, and comprises the following steps: collecting clinical blood sample data of pregnant women in the middle of pregnancy; extracting features in the clinical blood sample data, dividing search agent populations in the features into different clustering clusters, obtaining a guide vector from the centroid of the clustering cluster and the global mean of the population, performing aurora egg trajectory updating to obtain a current solution; fusing historical and current population members to construct a difference vector, applying disturbance to individuals, and obtaining an optimal solution under a set condition; converting a continuous problem space of the obtained optimal solution into a binary domain, feeding a classification error rate back to a fitness function, guiding a search process in a next generation population, and outputting an optimal biochemical indicator combination with the highest performance and the best explainability until a termination process is satisfied, which indicates a future direction for the precise prevention and personalized treatment of preeclampsia.

The present invention provides a pharmaceutical composition for treating or preventing preeclampsia, the pharmaceutical composition containing a VEGFR-2-specific ligand that activates VEGFR-2 without activating VEGFR-1.

The present invention relates to methods of diagnosing preeclampsia in a subject based on the quantitative level of one or more biomarkers in a sample from the subject. Also disclosed are methods of treating the subject diagnosed with preeclampsia.

A system includes a first sensor to generate a swelling signal based on a user pressing the first sensor with a body part, a second sensor to generate a blood signal indicative of a volume of blood in the body part when the user presses the first sensor, and a force sensor to measure a force applied to the first sensor by the body part when the user presses the first sensor. The system also includes a processor configured to determine an indication of swelling of the body part based on the swelling signal when the force sensor measures a first predetermined value, and determine an indication of blood pressure at the body part based on a force value measured by the force sensor when the blood signal reaches a second predetermined value.

This invention relates to the use of baicalin in the preparation of drugs for treating and / or alleviating preeclampsia. The drugs are used to inhibit ferroptosis in placental trophoblasts and / or placental tissue, manifested by increasing the expression level of at least one of GPX4, SLC7A11, and FTH1, increasing GSH content and / or GPX activity, and decreasing Fe... 2+ It can reduce MDA, lipid ROS and / or mitochondrial ROS levels, and improve preeclampsia-related hypertension, proteinuria, placental oxidative stress and adverse pregnancy outcomes. This application can be used to prepare preeclampsia treatment and / or alleviation drugs with baicalin monomer as the active ingredient.